Time to swing for the fences.
Complete Genomics became the world's first large-scale human genome sequencing company in 2008. It provides end-to-end outsourced human genome sequencing for its customers, which include academic and government research centers and pharmaceutical companies.
Some of these customers include Pfizer, Lilly, Broad Institute, The Institute for Systems Biology, Southwestern Medical Center, and The Children's Hospital of Philadelphia.
GNOM went public in November 2010 and its stock value has doubled in that timeframe. The applications and implications for the future of disease research are staggerin and this company is in position to become incredibly valuable as demand for its services increases.
There are other players in the game -- Pacific Biosciences, Illumina, Life Technologies Corporation, and Roche Holdings AG -- all sell DNA sequencers, and there are a lot of life sciences interests that do their own sequencing in-house. Complete Genome seems as though it will offer a cheaper alternative over time.
Extremely ambitious target. Confidence: 8.